Am J Psychiatry 156:974-975, June 1999
© 1999 American Psychiatric Association
Distinguishing Change in Primary and Secondary Negative Symptoms
GARY REMINGTON, M.D., PH.D., F.R.C.P.(C.),
SIOW-ANN CHONG, M.B.B.S., M.MED., and
SHITIJ KAPUR, M.D., F.R.C.P.(C.), PH.D.
Toronto, Ont., Canada
To the Editor: Clozapine, the prototype of atypical antipsychotics, has been noted to have a number of unique clinical features, including the improvement of negative symptoms, when compared with conventional neuroleptics (1). Subsequent studies with other novel neuroleptics also suggest clozapine's superior efficacy in this particular respect (2, 3).
Such claims are tempered by the argument that there is a distinction between primary, or deficit, and secondary negative symptoms (4). Specifically, it is suggested that the former may reflect more enduring psychopathological changes and are therefore less amenable to change, whereas the latter relate to state phenomena such as depression, extrapyramidal symptoms, or environmental deprivation.
Path analysis and multiple regression have been employed as statistical procedures to establish whether changes in negative symptoms with treatment reflect shifts in primary versus secondary negative symptoms. These procedures are used on the basis of the premise that a direct effect on primary symptoms can be established by controlling for, or covarying out, improvement in secondary negative symptoms. By using these techniques, it has been suggested that clozapine (5), risperidone (6), and more recently, olanzapine (7) each influence primary negative symptoms after the effects of the secondary negative symptoms are factored out.
There are several problems with such an approach. First, existing reports have not agreed on the identifiable secondary negative symptoms, with one study specifying only extrapyramidal and positive symptoms (6), whereas others have addressed these as well as depressive symptoms (5, 7). A second difficulty involves the possibility that other sources of secondary negative symptoms exist. For example, neurocognitive impairment is a common feature in schizophrenia and may be integrally related to negative symptoms (8, 9). While there are reports suggesting that novel antipsychotics are superior to conventional neuroleptics with respect to cognitive measures (10, 11), studies have not yet evaluated the potential impact that they could have on negative symptoms. Any investigation that omits variables that might contribute to secondary negative symptoms risks the possibility of erroneously attributing these changes to an influence on primary symptoms.
In light of these caveats, we must be cautious in evaluating claims that novel neuroleptics can improve true deficit symptoms. In fact, more recent work indicates that clozapine can influence secondary, but not primary, symptoms (12). The optimal approach to evaluating change in true deficit symptoms is one that employs a valid measure prospectively. Statistical procedures may be of value but only if they ensure that all possible contributing factors to secondary negative symptoms are included in the analysis.
REFERENCES
-
Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Group: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789–796[Abstract]
-
Carman J, Peuskens J, Vangeneugden A: Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int J Psychopharmacol 1995; 10:207–213
-
Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457–465[Abstract]
-
Carpenter WT Jr, Heinrichs DW, Wagman AMI: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145:578–583[Abstract/Free Full Text]
-
Miller DD, Perry PJ, Cadoret RJ, Andreasen NC: Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35:8–15[Medline]
-
Moller H-J, Muller H, Borison RL, Schooler NR, Chouinard G: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1995; 245:45–49[Medline]
-
Tollefson GD, Sanger TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154:466–474[Abstract]
-
Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321–330[Abstract/Free Full Text]
-
Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI: Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res 1997; 25:1–10[Medline]
-
Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H: Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996; 6:S2-13–S2-20
-
Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154:799–804[Abstract]
-
Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20–26[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
N. Tarrier
Negative Symptoms in Schizophrenia: Comments From a Clinical Psychology Perspective
Schizophr Bull,
April 1, 2006;
32(2):
231 - 233.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
